treatment
urgent
need
prevent
respiratori
failur
death
coronaviru
diseas
hydroxychloroquin
hcq
receiv
worldwid
attent
posit
result
small
studi
use
data
collect
routin
care
adult
french
hospit
document
pneumonia
requir
oxygen
lmin
emul
target
trial
aim
assess
effect
hcq
mgday
composit
primari
endpoint
transfer
intens
care
unit
icu
within
day
inclus
andor
death
caus
analys
adjust
confound
factor
invers
probabl
treatment
weight
studi
includ
patient
pneumonia
receiv
hcq
within
hour
admiss
hcq
group
nohcq
group
initi
sever
well
balanc
group
weight
analysi
patient
hcq
group
transfer
icu
die
within
day
vs
nohcq
group
vs
event
rel
risk
rr
ci
hcq
group
patient
die
within
day
vs
nohcq
group
vs
event
rr
ci
respect
develop
acut
respiratori
distress
syndrom
within
day
vs
event
rr
ci
eight
patient
receiv
hcq
experienc
electrocardiogram
modif
requir
hcq
discontinu
result
support
use
hcq
patient
hospitalis
document
hypox
pneumonia
whodeclar
pandem
sever
acut
respiratori
syndrom
coronaviru
caus
fatal
pneumonia
coronaviru
diseas
treatment
urgent
need
prevent
hypoxem
respiratori
failur
death
vitro
studi
document
potenti
activ
hydroxychloroquin
hcq
small
studi
releas
controversi
result
hcq
receiv
intens
worldwid
attent
effect
highli
contenti
one
uncontrol
french
studi
hospitalis
patient
pcr
nasopharyng
swab
suggest
hcq
dose
mgday
decreas
shed
combin
azithromycin
efficaci
howev
anoth
uncontrol
french
studi
found
evid
antivir
clearanc
hcq
azithromycin
hospitalis
patient
clinic
perspect
recent
studi
randomis
patient
two
parallel
group
one
control
group
one
receiv
hcq
treatment
mgd
day
found
reduct
time
clinic
recoveri
patient
howev
sever
ill
clinic
endpoint
clearli
defin
stratif
comorbid
associ
poor
outcom
base
result
neglig
cost
known
safeti
profil
hcq
drug
consid
potenti
use
patient
attract
enorm
attent
social
mass
media
receiv
fda
approv
sever
case
hand
fear
shortag
essenti
treatment
patient
rheumat
diseas
includ
system
lupu
erythemat
sle
recent
increas
question
safeti
patient
rais
due
lack
unbias
data
urgenc
confirm
possibl
clinic
efficaci
hcq
situat
design
emul
trial
use
observ
data
collect
realworld
set
patient
hospitalis
infect
requir
oxygen
primari
aim
evalu
clinic
effect
oral
hcq
daili
dose
mg
prevent
admiss
intens
care
unit
icu
andor
death
caus
secondari
aim
assess
effect
prevent
acut
respiratori
distress
syndrom
ard
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
use
data
collect
routin
care
emul
target
trial
aim
assess
effect
hcq
patient
hospitalis
infect
requir
oxygen
assess
patient
elig
physician
screen
electron
health
record
patient
hospitalis
march
four
french
tertiari
care
centr
provid
care
patient
pneumonia
adult
patient
elig
studi
age
year
year
pcrconfirm
infect
requir
oxygen
mask
nasal
prong
correspond
progress
score
exclus
criteria
presenc
contraind
hcq
mg
daili
includ
patient
dialysi
start
hcq
admiss
hospit
treatment
anoth
experiment
drug
tocilizumab
lopinavirritonavir
remdesivir
within
hour
admiss
organ
failur
requir
immedi
admiss
icu
continu
care
unit
ccu
ard
admiss
defin
need
noninvas
ventil
provis
posit
airway
pressur
invas
mechan
ventil
discharg
icu
standard
care
decis
limit
stop
activ
therapeut
made
admiss
opposit
data
collect
patient
herhi
legal
repres
studi
perform
accord
declar
helsinki
amend
receiv
approv
appropri
irb
number
pari
xii
univers
aphp
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
compar
two
treatment
strategi
initi
hcq
daili
dose
mg
first
hour
hospitalis
hcq
group
absenc
hcq
initi
twoday
period
nohcq
control
group
avoid
timedepend
bia
start
followup
baselin
time
zero
individu
time
hospit
admiss
end
followup
death
discharg
home
day
hospitalis
primari
outcom
composit
transfer
icu
within
day
inclus
andor
death
caus
secondari
outcom
allcaus
mortal
day
occurr
ard
patient
transfer
anoth
hospit
physician
contact
obtain
outcom
data
unsuccess
outcom
data
consid
miss
hcq
initi
day
afterward
patient
receiv
hcq
qt
prolong
assess
electrocardiogram
ecg
correct
heart
rate
bazett
fredericia
formula
invers
probabl
treatment
weight
iptw
approach
use
emul
randomis
balanc
differ
baselin
variabl
treatment
group
nonparsimoni
multivari
logist
regress
model
construct
estim
patient
probabl
receiv
hcq
given
baselin
covari
ie
propens
score
variabl
propens
score
ps
model
plan
prespecifi
outcom
analys
includ
age
gender
comorbid
presenc
chronic
respiratori
insuffici
oxygen
therapi
asthma
cystic
fibrosi
chronic
respiratori
patholog
like
decompens
viral
infect
heart
failur
nyha
iii
iv
chronic
kidney
diseas
liver
cirrhosi
childpugh
stage
b
person
histori
cardiovascular
diseas
hypertens
stroke
coronari
arteri
diseas
cardiac
surgeri
insulindepend
diabet
mellitu
diabet
microangiopathi
macroangiopathi
treatment
immunosuppress
drug
includ
anticanc
chemotherapi
uncontrol
hiv
infect
hiv
infect
cell
count
haematolog
malign
bmi
kgm
third
trimest
pregnanc
treatment
angiotensinconvert
enzym
inhibitor
acei
angiotensin
receptor
blocker
arb
time
sinc
symptom
onset
sever
condit
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
admiss
percentag
lung
affect
presenc
confus
respiratori
frequenc
oxygen
satur
without
oxygen
oxygen
flow
systol
blood
pressur
creactiv
protein
crp
mgl
nonlinear
effect
continu
variabl
consid
model
use
fraction
polynomi
standardis
differ
examin
assess
balanc
threshold
design
indic
clinic
meaning
imbal
outcom
analys
base
iptw
estim
rel
risk
rr
confid
interv
ci
deriv
varianc
estim
account
estim
propens
score
also
examin
outcom
subgroup
patient
better
prognosi
admiss
estim
qsofa
sever
sensit
analys
conduct
assess
robust
find
first
analys
unweight
sampl
second
perform
trim
analysi
truncat
extrem
weight
final
compar
result
analysi
exclud
patient
receiv
hcq
later
followup
ie
h
admiss
miss
data
either
transfer
icu
death
two
case
miss
data
ard
chose
imput
miss
data
statist
analys
perform
r
statist
packag
version
later
r
foundat
statist
comput
http
wwwrprojectorg
among
patient
elig
analysi
receiv
hcq
within
hour
admiss
although
receiv
hcq
later
median
age
patient
year
interquartil
rang
iqr
year
men
comorbid
less
frequent
hcq
group
median
delay
symptom
onset
admiss
hospit
day
iqr
day
overal
initi
sever
well
balanc
group
except
confus
admiss
hcq
group
vs
nohcq
group
tabl
iptw
analysi
patient
hcq
group
transfer
icu
die
within
day
compar
nohcq
group
among
patient
receiv
hcq
within
first
hour
experienc
ecg
modif
requir
hcq
discontinu
median
day
began
accord
french
nation
guidelin
among
correct
qt
interv
qtc
prolong
ms
includ
qtc
ms
one
patient
receiv
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
medic
might
interfer
cardiac
conduct
present
firstdegre
atrioventricular
block
day
hcq
treatment
note
patient
hcq
initi
day
admiss
nohcq
group
transfer
icu
day
afterward
prescrib
lopinavir
ritonavir
develop
left
bundl
branch
block
day
report
compar
studi
use
realworld
data
collect
routin
care
assess
efficaci
safeti
hcq
popul
patient
hospitalis
hypoxem
pneumonia
found
hcq
treatment
mgday
ad
standard
care
associ
reduct
admiss
icu
death
day
hospit
admiss
compar
standard
care
alon
rate
ard
decreas
either
popul
patient
hospitalis
requir
oxygen
similar
report
other
percentag
patient
transfer
icu
similar
report
chines
cohort
patient
hospitalis
pneumonia
clinic
featur
patient
includ
also
consist
report
predomin
men
patient
cardiovascular
comorbid
andor
obes
almost
patient
bilater
pneumonia
moder
sever
lung
infiltr
patient
studi
receiv
drug
particular
potenti
confound
antivir
antiinflammatori
treatment
includ
steroid
icu
admiss
time
antivir
treatment
initi
may
critic
reduc
viral
load
accordingli
recent
lopinavirritonavir
trial
posthoc
subgroup
analysi
suggest
lopinavirritonavir
could
clinic
benefit
start
earlier
day
onset
symptom
case
patient
median
time
symptom
onset
inclus
day
treat
hcq
soon
possibl
ie
hour
hospit
admiss
found
viral
rna
detect
patient
inclus
show
activ
viral
shed
previou
report
indic
hcq
expect
show
antivir
efficaci
check
subsequ
pcr
studi
therefor
reach
conclus
potenti
efficaci
decreas
viral
shed
although
may
appear
limit
use
robust
clinic
outcom
ie
death
icu
admiss
substanti
clinic
relev
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
pneumonia
progress
second
week
ill
associ
socal
cytokin
storm
thought
respons
clinic
worsen
mani
patient
patient
includ
studi
inflammatori
syndrom
defin
creactiveprotein
higher
mgl
suggest
cytokin
storm
syndrom
alreadi
begun
drug
decreas
viru
shed
may
therefor
inadequ
stage
mani
antiinflammatori
drug
current
test
tocilizumab
corticosteroid
other
despit
immunomodulatori
properti
hcq
includ
regul
product
proinflammatori
cytokin
endosom
inhibit
tolllik
receptor
play
major
role
innat
immun
respons
treatment
show
effect
specif
popul
final
hcq
block
potassium
channel
potenti
prolong
qtc
potenti
sever
consequ
sudden
cardiac
death
cardiac
arrhythmia
besid
qtc
prolong
observ
signific
cardiolog
event
studi
french
nation
drug
agenc
report
death
potenti
relat
hcq
sinc
promot
public
potenti
treatment
although
hcq
consid
safe
context
sle
advers
event
may
explain
use
highdos
hcq
elderli
patient
renal
impair
frequent
drug
interact
accordingli
neg
clinic
result
studi
argu
widespread
use
hcq
patient
pneumonia
studi
sever
limit
first
although
aim
emul
target
trial
use
robust
statist
techniqu
adjust
treatment
randomli
assign
potenti
unmeasur
confound
may
bia
result
second
four
potenti
import
prognost
variabl
could
balanc
ps
model
none
one
patient
hcq
group
present
variabl
accordingli
caution
requir
interpret
result
especi
overal
mortal
limit
number
event
observ
third
take
centr
effect
account
ps
model
number
patient
treat
hcq
centr
unbalanc
centr
treat
patient
hcq
other
conclus
found
hcq
significantli
reduc
admiss
icu
death
day
hospit
admiss
ard
hospitalis
patient
hypoxem
pneumonia
due
result
major
import
support
use
hcq
patient
hospitalis
document
pneumonia
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
financi
support
conflict
interest
author
declar
conflict
interest
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
supplementari
data
standardis
differ
variabl
use
gener
propens
score
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
